MARKET

KTTAW

KTTAW

Pasithea Therapeutics Corp
NASDAQ
0.0105
0.00
0.00%
Opening 09:30 02/09 EST
OPEN
--
PREV CLOSE
0.0105
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.1198
52 WEEK LOW
0.0100
MARKET CAP
--
P/E (TTM)
-0.0020
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KTTAW last week (0202-0206)?
Weekly Report · 9h ago
Weekly Report: what happened at KTTAW last week (0126-0130)?
Weekly Report · 02/02 09:27
Pasithea Therapeutics Corporation Held Special Shareholder Meeting
Reuters · 01/28 21:19
Weekly Report: what happened at KTTAW last week (0119-0123)?
Weekly Report · 01/26 09:26
Weekly Report: what happened at KTTAW last week (0112-0116)?
Weekly Report · 01/19 09:29
Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1
Reuters · 01/13 12:22
Pasithea Therapeutics Announces Data Release Timeline for PAS-004 Clinical Trials in NF1 and Advanced Cancer
Reuters · 01/13 12:02
PASITHEA THERAPEUTICS CORP - TO PRESENT NF1-PN STUDY DATA IN H2 2026
Reuters · 01/13 12:01
More
About KTTAW
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTAW stock methods without spending real money on the virtual paper trading platform.